Single-center Phase 2 Open-label Trial Evaluating Efficacy and Safety of Daratumumab in Treatment of Patients With Proliferative Glomerulonephritis With Monoclonal Immune Deposits and C3 Glomerulopathy Associated With Monoclonal Gammopathy
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Daratumumab (Primary) ; Aciclovir; Dexamethasone
- Indications Membranoproliferative glomerulonephritis
- Focus Adverse reactions
- 28 Jun 2021 Status changed from active, no longer recruiting to completed.
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.
- 18 Jun 2020 Planned End Date changed from 1 Sep 2020 to 1 May 2021.